Psychopharmacological neuroprotection in neurodegenerative disease: Assessing the preclinical data

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 22, Issue 1, 2010, Pages 8-18

  Lauterbach, Edward C ^a   Victoroff, Jeff ^d   Coburn, Kerry L ^b   Shillcutt, Samuel D ^b   Doonan, Suzanne M ^b   Mendez, Mario F ^c  

^a MERCER UNIVERSITY   (United States)

^b MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BUSPIRONE; CLONAZEPAM; DESIPRAMINE; DIAZEPAM; DIPHENHYDRAMINE; FLUOXETINE; LEVODOPA; LITHIUM; MAPROTILINE; MELATONIN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT; NORTRIPTYLINE; OLANZAPINE; OXCARBAZEPINE; PAROXETINE; PRAMIPEXOLE; PROTEASOME; QUETIAPINE; RISPERIDONE; ROPINIROLE; SEROTONIN UPTAKE INHIBITOR; TAU PROTEIN; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; ARTICLE; CELL FUNCTION; CELL VIABILITY; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG EFFECT; HUMAN; HUNTINGTON CHOREA; MITOCHONDRIAL RESPIRATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 76749090203     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.2010.22.1.8     Document Type: Article

References (34)

1. Alzheimer's Association: 2007. Alzheimer's Disease Facts and Figures. Chicago, Alzheimer's Association, 2007
2. Rice DP, Fillit HM, Max W, et al: Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. Am J Manag Care 2001; 7:809-818
3. Meek PD, McKeithan K, Schumock GT: Economic considerations in Alzheimer's disease. Pharmacotherapy 1998; 18:68-73
4. Silverman DH, Small GW, Chang CY, et al: Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001; 286:2120 - 2127
5. Brookmeyer R, Johnson E, Ziegler-Graham K, et al: Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007; 3:186-191
6. Layfield R, Cavey JR, Lowe J: Role of ubiquitin-mediated proteolysis in the pathogenesis of neurodegenerative disorders. Ageing Res Rev 2003; 2:343-356
7. Feany MB: New genetic insights into Parkinson's disease. N Engl J Med 2004; 351:1937-1940
8. Kharbanda S, Yuan ZM, Weichselbaum R, et al: Determination of cell fate by c-Abl activation in the response to DNA damage. Oncogene 1998; 17:3309-3318
9. Friedlander RM: Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 2003; 348:1365-1375
10. Zhang JH, Zhang Y, Herman B: Caspases, apoptosis and aging. Ageing Res Rev 2003; 2:357-366
11. Le Bras M, Rouy I, Brenner C: The modulation of inter-organelle cross-talk to control apoptosis. Med Chem 2006; 2:1-12
12. El-Guendy N, Rangnekar VM: Apoptosis by Par-4 in cancer and neurodegenerative diseases. Exp Cell Res 2003; 283:51-66
13. Kim R: Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun 2005; 333:336-343
14. Orrenius S, Gogvadze V, Zhivotovsky B: Mitochondrial oxidative stress: implications for cell death. Annu Rev Pharmacol Toxicol 2007; 47:143-183
15. Lemasters JJ, Qian T, Trost LC, et al: Confocal microscopy of the mitochondrial permeability transition in necrotic and apoptotic cell death. Biochem Soc Symp 1999; 66:205-222
16. Zhang JH, Xu M: DNA fragmentation in apoptosis. Cell Res 2000; 10:205-211
17. Swerdlow RH: Mitochondrial DN: A-related mitochondrial dysfunction in neurodegenerative diseases. Arch Pathol Lab Med 2002; 126:271-280
18. Shevell M, Ashwal S, Donley D, et al: Practice parameter: evaluation of the child with global developmental delay: report of the quality standards subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2003; 60:367-380
19. MDS Task Force: Management of Parkinson's disease: An evidence-based review: introduction. Mov Disord 2002; 17: S1-S6
20. Maurice T, Su TP, Privat A: Sigma1 (sigma 1) receptor agonists and neurosteroids attenuate B25-35-amyloid peptide-induced amnesia in mice through a common mechanism. Neuroscience 1998; 83:413-428
21. Soriano FX, Papadia S, Hofmann F, et al: Preconditioning doses of NMDA promote neuroprotection by enhancing neuronal excitability. J Neurosci 2006; 26:4509-4518
22. Ravina BM, Fagan SC, Hart RG, et al: Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurol 2003; 60:1234-1240
23. Stroke Therapy Academic Industry Roundtable: Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999; 30:2752-2758
24. Gladstone DJ, Black SE, Hakim AM: Heart and Stroke Foundation of Ontario Centre of Excellence in Stroke Recovery: toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions Stroke 2002; 33:2123-2136
25. Ford GA: Clinical pharmacological issues in the development of acute stroke therapies. Br J Pharmacol 2008; 153(suppl 1): S112-S119
26. Clarke CE: Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? Mov Disord 2008; 23:784-789
27. Mani RB: The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Stat Med 2004; 23:305-314
28. Tol J, Koopman M, Cats A, et al: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360:563-572
29. Whone AL, Bailey DL, Remy P, et al: A technique for standardized central analysis of 6-(18)F-fluoro-l-dopa PET data from a multicenter study. J Nucl Med 2004; 45:1135-1145
30. Gupta M, Gupta YK, Agarwal S, et al: A randomized, doubleblind, placebo controlled trial of melatonin add-on therapy in epileptic children on valproate monotherapy: effect on glutathione peroxidase and glutathione reductase enzymes. Br J Clin Pharmacol 2004; 58:542-547
31. Mohr DC, Goodkin DE, Islar J, et al: Treatment of depression is associated with suppression of nonspecific and antigenspecific T(H)1 responses in multiple sclerosis. Arch Neurol 2001; 58:1081-1086
32. Parkinson Study Group: Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287:1653-1661
33. Rakshi JS, Pavese N, Uema T, et al: A comparison of the progression of early parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study. J Neural Transm 2002; 109:1433-1443
34. Gordon PH, Moore DH, Miller RG, et al: Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007; 6:1045-1053